Use of proprietary multivariate serum biomarker algorithmic panels — including ROMA, OVA1, Overa, OvaWatch, and substantially similar assays — is not endorsed by the National Comprehensive Cancer Network (NCCN) for determining the status of an undiagnosed adnexal or pelvic mass. NCCN guidance emphasizes history and physical examination, imaging (primarily transvaginal ultrasonography with cross-sectional imaging when indicated), and clinician judgment including gynecologic oncology evaluation rather than routine reliance on these proprietary panels for initial diagnostic determination or referral decision-making. Consequently, these panels are excluded from medically necessary services under this policy.

These assays are considered not medically necessary because the available evidence focuses on diagnostic accuracy rather than clinical outcomes. Accuracy studies commonly use postsurgical histology or short-term follow-up as reference standards and have methodological limitations (high or unclear risk of bias, selected high-prevalence populations, inconsistent thresholds, and variable reporting). Importantly, no trials or prospective comparative studies reliably demonstrate that use of OVA1, ROMA, Overa, or OvaWatch improves referral appropriateness, selection of surgical setting, completeness of staging or debulking, perioperative morbidity, survival, quality of life, or downstream resource use compared with standard clinical, imaging, and laboratory evaluation.

Multivariate serum biomarker algorithms combine measurements of multiple serum proteins with a proprietary algorithm to generate a single risk estimate that classifies an adnexal or pelvic mass as higher- or lower-risk for malignancy. Examples include OVA1, ROMA, Overa, and OvaWatch. These tests are intended as adjuncts for preoperative risk stratification — not for screening or as standalone diagnostic tools — and labeling for FDA-authorized assays indicates they should be used in conjunction with clinical and radiologic evaluation.